

## Fibryga® (fibrinogen [human]) - New indication

- On July 31, 2024, the <u>FDA approved</u> Octapharma's <u>Fibryga (fibrinogen [human])</u>, for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
- Fibryga is also approved for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
- The approval of Fibryga for the new indication was based on a randomized, controlled, singleblinded study in adult cardiac surgical patients for whom fibrinogen supplementation was ordered in accordance with accepted clinical standards. Patients were randomly assigned to receive either Fibryga or cryoprecipitate.
  - Fibryga was demonstrated to be non-inferior to cryoprecipitate based on the total number of units of allogeneic blood products administered during the first 24 hours after termination of cardiopulmonary bypass.
- The most common adverse reactions (> 5%) with Fibryga use for acquired fibrinogen deficiency were abnormal hepatic function, acute kidney injury, anemia, atrial fibrillation, delirium and renal failure.
- The recommended intravenous dose of Fibryga for the treatment of acquired fibrinogen deficiency is as follows:
  - For adults: 4 g
  - For adolescents age ≥ 12 years: 50 mg/kg body weight
  - For children age < 12 years: 70 mg/kg body weight</p>
  - Additional doses can be administered as needed to bleeding patients when plasma fibrinogen level is ≤ 200 mg/dL or thromboelastometry FIBTEM A10 is ≤ 10 mm (or equivalent values generated by other viscoelastic testing methods). Dosing may be adjusted depending on plasma fibrinogen levels or viscoelastic testing, severity of bleeding, body weight, or patient's clinical condition.
- Refer to the Fibryga drug label for dosing for congenital fibrinogen deficiency.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.